AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AstraZeneca PLC (AZN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and hedge fund interest outweigh the recent negative news and overbought technical indicators. The stock's growth potential and robust pipeline make it a solid choice for long-term investment.
The MACD is positive and contracting, indicating bullish momentum. The RSI is at 88.599, signaling the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near resistance levels (R1: 203.553). While the RSI suggests caution, the overall trend remains positive.
Hedge funds are significantly increasing their holdings, with a 166.61% rise in buying activity.
Strong financial performance in Q3 2025, with revenue up 11.99% YoY, net income up 77.26% YoY, and EPS up 78.02% YoY.
Analysts from Citi and Berenberg have issued Buy ratings with high price targets, citing AstraZeneca's strong pipeline and growth potential.
AstraZeneca's commitment to health equity initiatives, with $3.4 million awarded to nonprofits, enhances its corporate reputation.
Legal risks in China due to the indictment of the former president of AstraZeneca's China operations.
The NIH discontinuing a trial arm due to safety concerns, which could impact investor confidence.
Overbought technical indicators (RSI at 88.599), suggesting a potential short-term pullback.
In Q3 2025, AstraZeneca demonstrated strong financial growth: Revenue increased by 11.99% YoY to $15.19 billion, net income rose by 77.26% YoY to $2.53 billion, and EPS grew by 78.02% YoY to 1.62. However, the gross margin slightly declined by 0.81% YoY to 81.17.
Analyst sentiment is mixed but leans positive. Citi and Berenberg issued Buy ratings with high price targets, citing AstraZeneca's strong pipeline and growth potential. JPMorgan maintains an Overweight rating and added the stock to its European Analyst Focus List. However, Deutsche Bank maintains a Sell rating, citing concerns about valuation.
